We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
XBiotech Xilonix Positive in Phase III Colorectal Cancer Study
Read MoreHide Full Article
XBiotech, Inc. (XBIT - Free Report) announced positive results from a phase III study on its lead candidate, Xilonix, for the treatment of advanced colorectal cancer (CRC).
Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth and spread of tumors, and mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer.
Patients (n=309) enrolled in the study were randomized in the ratio of 2:1 to receive either Xilonix plus best supportive care (BSC) or placebo plus BSC.
Data from the study revealed a 76% relative improvement in the clinical response rate (CRR) after 8 weeks of therapy compared to placebo. Patients treated with Xilonix also demonstrated a clinical benefit. The candidate was generally well tolerated. Notably, there was a lack of toxicity associated with Xilonix in the study. Results were presented at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer.
The study was developed in collaboration with the Scientific Advice Working Group at the European Medicines Agency (EMA). In Apr 2016, the EMA’s the Committee for Medicinal Products for Human Use (CHMP) granted accelerated review to Xilonix for the treatment of advanced CRC. A decision on the product’s marketing approval should be out as early as the fourth quarter of 2016.
Meanwhile, in the U.S., Xilonix is in phase III studies and the candidate enjoys Fast Track status for the treatment of advanced colorectal cancer. We expect investor focus to remain on further development updates on Xilonix from the company.
CRC, the second leading cause of malignancy, is estimated to be diagnosed in approximately 470,000 individuals in the EU this year.
Drugs that are currently approved for the treatment of CRC include Erbitux, Stivarga, Zaltrap (in combination with chemotherapy) and Cyramza (in combination with FOLFIRI).
XBiotech currently carries a Zacks Rank #2 (Buy). Investors interested in the health care sector may also consider Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pfizer Inc. (PFE - Free Report) . Each stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
XBiotech Xilonix Positive in Phase III Colorectal Cancer Study
XBiotech, Inc. (XBIT - Free Report) announced positive results from a phase III study on its lead candidate, Xilonix, for the treatment of advanced colorectal cancer (CRC).
Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth and spread of tumors, and mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer.
Patients (n=309) enrolled in the study were randomized in the ratio of 2:1 to receive either Xilonix plus best supportive care (BSC) or placebo plus BSC.
Data from the study revealed a 76% relative improvement in the clinical response rate (CRR) after 8 weeks of therapy compared to placebo. Patients treated with Xilonix also demonstrated a clinical benefit. The candidate was generally well tolerated. Notably, there was a lack of toxicity associated with Xilonix in the study. Results were presented at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer.
The study was developed in collaboration with the Scientific Advice Working Group at the European Medicines Agency (EMA). In Apr 2016, the EMA’s the Committee for Medicinal Products for Human Use (CHMP) granted accelerated review to Xilonix for the treatment of advanced CRC. A decision on the product’s marketing approval should be out as early as the fourth quarter of 2016.
Meanwhile, in the U.S., Xilonix is in phase III studies and the candidate enjoys Fast Track status for the treatment of advanced colorectal cancer. We expect investor focus to remain on further development updates on Xilonix from the company.
CRC, the second leading cause of malignancy, is estimated to be diagnosed in approximately 470,000 individuals in the EU this year.
Drugs that are currently approved for the treatment of CRC include Erbitux, Stivarga, Zaltrap (in combination with chemotherapy) and Cyramza (in combination with FOLFIRI).
XBiotech currently carries a Zacks Rank #2 (Buy). Investors interested in the health care sector may also consider Bristol-Myers Squibb Company (BMY - Free Report) , ANI Pharmaceuticals, Inc. (ANIP - Free Report) and Pfizer Inc. (PFE - Free Report) . Each stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>